Last update 15 Dec 2025

4SCAR-CD38

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
4SCAR CD38, 4SCAR38, 4SCARCD38
Target
CD38
Action
inhibitors
Mechanism
CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), Cell replacements, Gene transference(Gene transference)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Chronic Lymphocytic LeukemiaCD19 Expressing MalignanciesAnemia, Refractory, With Excess of Blasts+ [1]
Inactive Indication
Acute Myeloid LeukemiaB-Cell LeukemiaCD19 positive Acute Lymphoblastic Leukemia+ [2]
Originator Organization
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
Active Organization
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with 4SCAR-CD38
NCT03125577
/ RecruitingPhase 1/2IIT
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
NCT04016129
/ Unknown statusPhase 1/2IIT
CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
NCT03291444
/ RecruitingPhase 1IIT
A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes
100 Clinical Results associated with 4SCAR-CD38
Login to view more data
100 Translational Medicine associated with 4SCAR-CD38
Login to view more data
100 Patents (Medical) associated with 4SCAR-CD38
Login to view more data
100 Deals associated with 4SCAR-CD38
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
01 Aug 2025
B-Cell LeukemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2019
CD19 Expressing MalignanciesPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2019
CD19 positive Acute Lymphoblastic LeukemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2019
Acute Myeloid LeukemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2017
Plasma Cell LeukemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2017
Relapse multiple myelomaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
15 Jul 2017
Anemia, Refractory, With Excess of BlastsPhase 1
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
05 May 2018
Refractory LeukemiaPhase 1
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
05 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free